A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation  by Kliewer, Steven A. et al.
Cell, Vol. 83, 813-819, December 1, 1995, Copyright 0 1995 by Cell Press 
A Prostaglandin J2 Metabolite 
Binds Peroxisome Proliferator-Activated Receptor y 
and Promotes Adipocyte Differentiation 
Steven A. Kliewer,’ James M. Lenhard,” 
Timothy M. Willson,t lnder Patel,* 
David C. Morris,5 and Jiirgen M. Lehmann’ 
*Department of Cell Biology 
tDepartment of Medicinal Chemistry 
*Department of Molecular Biology 
SDepartment of Molecular Pharmacology 
Glaxo Research Institute 
Five Moore Drive 
Research Triangle Park, North Carolina 27709 
Summary 
Prostaglandins (PGs) of the Jz series form in vivo and 
exert effects on a variety of biological processes. 
While most PGs mediate their effects through G pro- 
tein-coupled receptors, the mechanism of action for 
the JL series of PGs remains unclear. Here, we report 
that PGJ? and its derivatives are efficacious activators 
of peroxisome proliferator-activated receptors a and 
y (PPARa and PPART, respectively), orphan nuclear 
receptors implicated in lipid homeostasis and adipo- 
cyte differentiation. The PGJ2 metabolite lgdeoxy- 
A12,t4-PGJ2 binds directly to PPARy and promotes effi- 
cient differentiation of C3HlOT1/2 fibroblasts to 
adipocytes. These data provide strong evidence that 
a fatty acid metabolite can function as an adipogenic 
agent through direct interactions with PPARy and, fur- 
thermore, suggest a novel mechanism of action for 
PGs of the J2 series. 
Introduction 
The prostaglandins (PGs) are a family of structurally re- 
lated molecules that are produced by cells in response to 
a variety of extrinsic stimuli and regulate cellular growth, 
differentiation, and homeostasis (reviewed by Smith, 
1989, 1992). PGs are derived from fatty acids, primarily 
arachidonic acid, which are released from membrane 
phospholipids by the action of phospholipases. Arachi- 
donic acid is first converted to an unstable endoperoxide 
intermediate by cyclooxygenase, and subsequently con- 
verted to one of several related products, including PGD,, 
PGEn, PGF*a, prostacyclin (PG12), and thromboxane API 
through the actions of specific PG synthetases. Each of 
these products has been shown to affect levels of second 
messengers through interactions with G protein-coupled 
receptors with seven transmembrane domains (Hirata et 
al., 1994; reviewed by Smith, 1992). 
PGD, is a major cyclooxygenase product in a variety of 
tissues and cells and has marked effects on a number of 
biological processes, including platelet aggregation, re- 
laxation of vascular and nonvascular smooth muscle, and 
nerve cell function (reviewed by Giles and Leff, 1988). 
PGD2 has also been shown to be released by mast cells, 
suggesting a role in immunologic responses (Lewis et al., 
1982). While PGDB is known to mediate effects through 
interactions with a cell surface receptor (Hirata et al., 
1994), PGD, readily undergoes dehydration in vivo and in 
vitro to yield additional, biologically active PGs of the JZ 
series (Fitzpatrick and Wynalda, 1983; Kikawa et al., 1984; 
Hirataet al., 1988). Membersof the PGJz series have been 
reported to have their own unique spectrum of biological 
effects, including the inhibition of cell cycle progression, 
the suppression of viral replication, the induction of heat 
shock protein expression, and the stimulation of os- 
teogenesis (reviewed by Fukushima, 1992). In contrast 
with the case of PGD2, the mechanism of action for the 
Jp series of PGs remains unclear. The observation that at 
least one of the PGJ2 series, A’*-PGJ2, is actively incorpo- 
rated into the nucleus of cells and associated with proteins 
(Narumiya et al., 1987) has led to speculation that these 
PGs may exert theireffectsthrough direct interactionswith 
intracellular proteins. 
Peroxisome proliferator-activated receptors (PPARs) 
are members of the nuclear receptor superfamily of ligand- 
activated transcription factors that includes the steroid, 
retinoid, and thyroid hormone receptors. To date, three 
mammalian PPAR subtypes have been isolated and 
termed PPARa, NUCl (also known as PPARG), and 
PPARy (reviewed by Keller and Wahli, 1993). Several ob- 
servations suggest that the PPARs play a physiologic role 
in the modulation of lipid metabolism. First, PPAR-binding 
sites have been identified in the regulatory regions of a 
number of genes encoding proteins involved in lipid me- 
tabolism. Furthermore, PPARs have been shown to be 
activated by high concentrations of a diverse group of lip- 
ids and lipid-like compounds, including peroxisome prolif- 
erators and long-chain fatty acids. Finally, PPARy is abun- 
dantly expressed in adipocytes and functions as a key 
regulator of adipocyte differentiation (Tontonoz et al., 
1994a, 1994b; Chawla et al ., 1994). Thus, PPARs appear 
to have a broad role in the regulation of lipid homeostasis. 
We recently showed that a class of antidiabetic com- 
pounds with potent adipogenic properties, termed thiazoli- 
dinediones, are high affinity PPARy ligands (Lehmann et 
al., 1995). However, naturally occurring ligands for the 
PPARs have yet to be identified. The observation that 
PPARs are activated in transient transfection assays by 
the synthetic arachidonic acid analog 5,8,1 l,lCeico- 
satetraynoic acid (ETYA) and high concentrations of ara- 
chidonic acid (Gbttlicher et al., 1992; Keller et al., 1993; 
Banner et al., 1993) raised the intriguing possibility that 
arachidonic acid metabolites might serve as PPAR li- 
gands. Here, we report that the cyclooxygenase product 
PGD2 and its PGJ2 derivatives are efficacious activators 
of PPARa and PPARy. Furthermore, the PGJ*dehydration 
product 15-deoxy-A’Z, 14-PGJ, is shown to bind directly to 
PPARy and to promote adipogenesis of cultured fibro- 
blasts. These data suggest that the Jp series of PGs may 
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exert their biological effects in part through activation of 
the PPAR signaling pathways. 
Results 
PGLh and Its PGJ2 Metabolites Are 
PPARy Activators 
As part of an effort to identify natural PPAR ligands, a large 
number of arachidonic acid derivatives were screened in 
a transient transfection assay. An established chimera 
system was used, in which the ligand-binding domains of 
the three murine PPAR subtypes were fused to the DNA- 
binding domain of the yeast transcription factor GAL4 (Leh- 
mann et al., 1995). Expression plasmids for the GAL4- 
PPAR chimeras were transfected into CV-1 cells together 
with a chloramphenicol acetyltransferase (CAT) reporter 
construct containing five copies of the GAL4-binding site 
upstream of the minimal thymidine kinase (tk) promoter. 
As previously shown (Lehmann et al., 1995), all three 
PPAR chimeraswere activated by 1 x 1 Om4 M of the peroxi- 
some proliferator Wyl4,643 (Figure 1). The PPARa and 
PPARy chimeras were also activated in the presence of 
1 x 10e5 M ETYA, and, to a lesser extent, arachidonic 
acid (Figure 1). interestingly, analysis of cyclooxygenase 
metabolites of arachidonic acid revealed PGD2 to be an 
efficacious activator of the PPARa and PPARy chimeras 
at a concentration of 1 x 1O-5 M (Figure 1). The efficacy 
of PGD2 in activating PPARy was comparable to that of the 
thiazolidinedione BRL49653, which we recently showed to 
be a high affinity PPARy ligand (Lehmann et al., 1995). 
Little or no activation of the NUCl chimera was detected 
in the presence of these PGs (Figure 1). 
The potency of PGl& in the activation of the PPARa and 
PPARy chimeras was examined next. In dose-response 
analysis, the activities of the PPARa and PPARy chimeras 
failed to plateau at PGDZ concentrations up to 1 x 10m5 
M (Figures 2A and 28, open squares). Thus, while PGDz 
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Figure 1. PGD? Is an Efficacious Activator of PPARu and PPARy 
CV-1 cells were transiently transfected with expression plasmids for 
the PPARu-GAL4, NUCl-GAL4, or PPARy-GAL4 chimeras and the 
reporter plasmid (UAS)&k-CAT. Cells were treated for 24 hr with either 
vehicle(O.l% DMSO), 1 x 10m4 M Wy14,643, or 1 x 10d5 M BRL49653, 
arachidonic acid, ETYA, or various PGs. Cell extracts were subse- 
quently assayed for CAT activity. 
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Figure 2. PPARa and PPARy Dose Response to PGD, and Its PGJ2 
Metabolites 
CV-1 cells were cotransfected with expression plasmids for the 
PPARa-GAL4 (A) or PPARy-GAL4 (8) chimeras and the reporter plas- 
mid (UAS)5-tk-CAT and treated with the indicated concentrations of 
PGD, (squares), PGJ2 (circles), A’*-PGJz (triangles), or 15deoxy 
A’*, j4-PGJ2 (diamonds). Cell extracts were subsequently assayed for 
CAT activity. 
(C) PGD2 metabolic pathway leading to the formation of PGJ*, A”- 
PGJ,, and 15-deoxy-A’*, “-PGJ2. 
is an efficacious activator of the PPARs, it lacks potency 
in its induction of these orphan receptors. 
The efficacy of PGD2 in activating the PPARa and 
PPARy chimeras coupled with its relative lack of potency 
suggested that PGD2 might be metabolized in CV-1 cells 
to more potent PPAR activators. Indeed, PGD2 is known 
to be readily metabolized in vitro and in vivo to yield the 
J2 series of PGs (Figure 2C). Incubation of PGD2 in the 
presence of human plasma or human serum albumin re- 
sults in the rapid accumulation of several major dehydra- 
tion and isomerization products, including A12-PGJ2 and 
15-deoxy-A”, j4- PGJ2 (Fitzpatrick and Wynalda, 1983; Ki- 
kawa et al., 1984). Ai2-PGJ2 has been shown to be asignifi- 
cant PGD, metabolite present in human and monkey urine, 
indicating that the Jp series of PGs also form in vivo (Hirata 
et al., 1988). 
In cotransfection assays, the three J-ring PGs were effi- 
cacious activators of both the PPARa and PPARy chime- 
ras (Figures 2A and 2B). Interestingly, 15-deoxy-A12, 14- 
PGJ2 was significantly more potent than its precursors in 
the activation of the PPARy chimera. The PPARy chimera 
responded to 15-deoxy-A12s 14-PGJn at concentrations as 
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low as 100 nM and with an EC0 of 2 uM (Figure 28). The 
results were not dependent upon the use of the chimera 
system, as similar data were obtained by using the wild- 
type PPARyl and a reporter construct driven by the adipo- 
cyte fatty acid-binding protein (aP2) enhancer containing 
two PPAR response elements (data not shown; Tontonoz 
et al., 1994a). These data are reminiscent of those ob- 
tained with the retinoid X receptor (RXR): RXR is activated 
by high concentrations of all-frans retinoic acid through 
isomerization of a fraction of the compound to the high 
affinity RXR ligand 9-cis retinoic acid (Heyman et al., 1992; 
Levin et al., 1992). 
Dose-response analysis performed with the PPARa 
chimera in the presence of PGD2 and the Jp series of PGs 
revealed a markedly different activation profile. While the 
PPARa chimera responded to high concentrations of the 
J-ring PGs, PGD2was the most potent of these compounds 
(Figure 2A). The differential responsiveness of PPARa and 
PPARy to PGDe and its PGJ* metabolites is consistent 
with previous studies demonstrating that the PPAR sub- 
types are pharmacologically distinct (Kliewer et al., 1994; 
Lehmann et al., 1995). 
PGs of the Jz Series Bind Directly to PPARy 
We previously showed that the thiazolidinedione 
BRL49653 binds to PPARy with a Kd of approximately 40 
nM (Lehmann et al., 1995). The ability of PGD2 and its 
metabolites to interact directly with PPARy was assessed 
in a competition binding assay using [3H]BRL49653 and 
the ligand-binding domain of PPARy expressed in Esche- 
richia coli. As expected, unlabeled BRL49653 efficiently 
displaced PHlBRL49653 from the PPARy ligand-binding 
domain (Figure 3A). Notably, 15deoxy-A’” 14-PGJ2 also 
competed efficiently with [3H]BRL49653, indicating that 
this PGJz derivative can interact directly with PPARy. 
Weaker but reproducible competition was also detected 
with PGJll and A”-PGJz (Figure 3A). No competition was 
observed with PGD*, PGE2, and PGF2a (Figure 3A). We 
note that the relative potencies of PGD2 and PGJ2 were 
reversed in the competition binding and PPARy transacti- 
vation assays. A number of potential explanations for this 
disparity exist, including the possibilities that these com- 
pounds are differentially metabolized in the two assays or 
are transported with different kinetics in the cell-based 
transfection assay. In control experiments, 15-deoxy- 
Ai’, 14-PGJ2 at a concentration of 1 x 10m5 M failed to 
compete with [3H]estradiol for binding to bacterially ex- 
pressed estrogen receptor ligand-binding domain (data 
not shown). Thus, lddeoxy-Aq2, 14-PGJ2 can interact di- 
rectly and specifically with PPARy. 
A complete dose-response analysis was performed 
with 15-deoxy-A12~ 14-PGJ2 in the competition binding 
assay. 15-Deoxy-A”, 14-PGJ2 displaced [3H]BRL49653 
binding to the PPARy ligand-binding domain with a Ki of 
2.5 uM (Figure 3B). These data are in good agreement 
with the EC& of 15-deoxy-A ‘2~14-PGJ2 for PPARy activation 
in the transient transfection assay (Figure 28) and provide 
evidence that a fatty acid metabolite can activate a PPAR 
through direct interactions with the ligand-binding domain 
of the receptor. 
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Figure 3. 15-Deoxy-A’*, j4-PGJ2 Binds PPARy 
(A) Competition binding assayswere performed using histidine-tagged 
PPARy ligand-binding domain protein and 10 nM [W]BRL49853 in the 
presence of vehicle (1% DMSO) or 50 uM unlabeled BRL49653 or 
PGs. Data shown are the mean of assays performed in triplicate f 
standard deviation. 
(B) Competition binding assays were performed with histidine-tagged 
PPARy ligand-binding domain fusion protein and 10 nM 13H]BRL49653 
in the presence of the indicated concentrations of unlabeled iBdeoxy- 
A’* “-PGJ2 as competitor. 
15Deoxy-A’*, 14-PGJz Promotes 
Adipocyte Differentiation 
PPARy is abundantly expressed in adipocytes, and its ec- 
topic expression in fibroblasts has been shown to result 
in adipocyte differentiation (Tontonoz et al., 1994a, 1994b; 
Chawla et al., 1994). We recently showed that treatment of 
murineC3HlOT112fibroblastswith the highaffinity PPARy 
ligand BRL49653, an antidiabetic thiazolidinedione, in- 
duces their efficient conversion to adipocytes as mea- 
sured by induction of adipocyte-specific genes and lipid 
accumulation (Lehmann et al., 1995). Thus, activation of 
PPARy is sufficient to initiate the entire adipogenic signal- 
ing cascade. 
If PGs of the Jp series can function as signaling mole- 
cules in vivo, these compounds might likewise be ex- 
pected to promote adipocyte differentiation of C3Hl OT1/2 
cells. To test this possibility, C3HlOT112 cells were treated 
with 15-deoxy-Ai” 14-PGJ2 and related PGs for 4 days and 
assayed for [3H]glucose incorporation into total cellular 
lipid as a measure of lipogenesis. Lipogenesis is an estab- 
lished measure of adipocyte differentiation (Moody et al., 
1974). Lipogenesis was stimulated approximately 1 l-fold 
in the presence of 1 x 1O-5 M 15-deoxy-Al*, 14-PGJ2 and 
with an EC& of 7 uM (Figure 4A; Table 1). Adipocyte differ- 
entiation was confirmed by oil red 0 staining for lipid drop- 
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let acctimulation in the cytoplasm of 15-deoxy-A’*, 14-PGJ2- 
treated cells (Figure 46). For comparative purposes, 
ciglitazone, a thiazolidinedione with an ECso of 3 VM for 
PPARy activation (Lehmann et al., 1995), was tested. Cigli- 
tazone stimulated lipogenesis to a similar degree as 15 
deoxy-Aj2, j4 -PGJn and with an EC&, of 4 PM (Figure 4A; 
Table 1). As expected, the thiazolidinedione BRL49653 
was the most potent compound in the assay, inducing 
lipogenesis 1 a-fold at 1 x 1 Oe5 M with an EC& of approxi- 
mately 90 nM (Figure 4A; Table 1). Lipogenesis in 
C3HlOT1/2 cells was stimulated to a lesser degree by 
treatment with PGD,, A’*-PGJ,, and PGJ2 (Figure 4A). 
Taken together, these data provide strong evidence that 
the arachidonic acid derivative 15-deoxy-A1’s 14-PGJ2 can 
function through PPARy to promote adipocyte differen- 
tiation. 
Discussion 
PGDz is known to play an important role in a number of 
biological processes, presumably through interactions 
with its cognate G protein-coupled receptor. The finding 
that PGD2 readily undergoes dehydration to the Jp series 
of PGs both in vitro and in vivo (Fitzpatrick and Wynalda, 
1983; Kikawa et al., 1984; Hirata et al., 1988) coupled 
with the effects of the J-ring PGs on various biological 
processes in vitro (reviewed by Fukushima, 1992) sug- 
gested the existence of a second PGDz signaling pathway. 
Our data demonstrate that the PGJz metabolites of PGDz 
are efficacious activators of PPARa and PPARy, sug- 
gesting that the biological effects of these molecules may 
be mediated at least in part through activation of nuclear 
receptor signaling cascades. 
Several previousobservations have indicated that PGD, 
and its J-ring metabolites might exert effects through inter- 
actions with intracellular proteins. First, the two PGDz syn- 
thetases identified to date, responsible for the conversion 
of PGHP to PGD2, are localized predominantly in the cyto- 
sol of cells (Shimuzu et al., 1979; Urade et al., 1989). This 
contrasts with the other characterized PG synthetases, 
which are present in the microsomal fraction (reviewed by 
Giles and Leff, 1988). Second, radiolabeled A,“-PGJ2 has 
been reported to be actively incorporated into cells and 
transferred to the nucleus, where it is associated with pro- 
teins (Narumiya et al., 1987). Finally, PGD,, PGJ2, and 
A”-PGJ2 have been shown to bind with high affinity to 
liver fatty acid-binding protein (L-FABP), an intracellular 
Table 1. ECso Values of PPARy Ligands in the C3HiOT112 Cell 
Lipogenesis Assay 
Compound EC&M) 
BRL49653 0.087 + 0.0010 
Ciglitazone 3.9 f 0.72 
1 5-Deoxy-A’Z,‘4-PGJ2 7.0 f 0.43 
C3HlOT112 cells were treated for 4 days with ten different concentra- 
tions of each compound in the range of 0.02-l 0.00 KM, and 13H]glu- 
case incorporation into total lipid was subsequently measured. The 
EC, values f standard deviations are shown. 
B 
Vehicle 
Figure 4. 15.Deoxy-A’*, 14-PGJ2 Treatment Promotes Adipocyte Differ- 
entiation of C3H1 OT112 Cells 
(A) [3H]glucose incorporation into total lipid (lipogenesis) was mea- 
sured in C3HlOT112 cells treated for 4 days with vehicle alone (0.1% 
DMSO) or 1 x 10m5 M df the indicated PGs or thiazolidinediones. 
Data are plotted as fold activation in lipogenesis relative to vehicle 
treatment. 
(B) C3HlOT112 cells were treated for 5 days with vehicle alone (0.1% 
DMSO) or 1 x 1 Om5 M 15deoxy-i\‘*, 14-PGJ2 and subsequently stained 
for lipid droplet accumulation with oil red 0. Magnification is 85 x 
protein involved in the uptake, intracellular transport, and 
metabolism of free fatty acids and their acyl-CoA esters 
(Khan and Sorof, 1990). L-FABP is a member of a family 
of lipid carrier proteins that includes the cellular retinol- 
binding proteins and cellular retinoic acid-binding pro- 
teins (Sweetser et al., 1986). This raises the interesting 
possibility that the FABPs and retinoid binding proteins 
may play analogous roles in the PPAR and retinoid recep- 
tor signaling pathways, respectively. 
Colocalization of PPARs with PGD, 
and PGD2 Synthetase 
We have demonstrated that PPARa and PPARy are effi- 
ciently activated by PGD, and its PGJ2 derivatives at con- 
centrations in the high nanomolar and low micromolar 
range. These data raise the following question: are PGDz 
and its PGJ2 metabolites present in vivo at sufficient con- 
centrations to serve as physiologic PPAR activators? 
While PGD2 and A”-PGJ2 are known to form in vivo (No- 
wak and Wennmalm, 1979; Hirata et al., 1988,, the rapid 
metabolism and potential for sequestration of these com- 
pounds by binding proteins complicates the quantitation 
of their levels. Little is known regarding the in vivo levels 
of the Jn series of PGs other than that A12-PGJ, is present 
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in human and monkey urine in significant quantities (- 150 
ng124 hr in human males) (Hirata et al., 1988). Higher 
amounts of other, uncharacterized A”-PGJ2 immunoreac- 
tive compounds have also been detected in human urine 
(Hirata et al., 1988). 
Several groups have examined the levels of PGDz 
formed from endogenous arachidonic acid in homoge- 
nates from various tissues. In two studies, PGD* was found 
to be most abundant in extracts prepared from rat spleen, 
with concentrations of IO-30 ,uM reported (Chiabrando 
et al., 1984; Ujihara et al., 1988). PGD2 synthetase, the 
enzyme responsible for PGDz formation, was likewise 
found to be most abundant in spleen as determined by 
both enzymatic activity in tissue homogenates and immu- 
nohistochemistry(Ujiharaet al., 1988; Urade et al., 1989). 
Interestingly, PPARy was recently shown by in situ hybrid- 
ization analysis to be abundantly expressed in both the 
red and the white pulp of the rat spleen, indicating a poten- 
tial role in energy metabolism in the immunesystem (Brais- 
sant et al., 1996). PPARa is also expressed in the red and 
white pulpof the rat spleen, albeit at lower levels (Braissant 
et al., 1996). The colocalization of PPARa and PPARy with 
PGD, synthetase activity in spleen suggests that PGD2 
metabolites may serve as PPAR ligands in this tissue. 
PGD* synthetase activity has also been demonstrated 
in intestine, lung, and liver, tissues in which PPARa, 
PPARy, or both are expressed (Chiabrando et al., 1984; 
Ujihara et al., 1988; Urade et al., 1989; lsseman and 
Green, 1990; Kliewer et al., 1994; Tontonoz et al., 1994a; 
Braissant et al., 1996). Thus, PGD2 metabolites may serve 
as physiologic PPAR ligands in these tissues. 
A Potential Role for PGD2 Metabolites 
in Adipocyte Differentiation 
PPARy is selectively expressed in adipocytes and was 
recently shown to play a pivotal role in adipocyte differenti- 
ation (Chawla et al., 1994; Tontonoz et al., 1994a, 1994b; 
Lehmann et al., 1995). Our demonstration that 15deoxy- 
A”, 14-PGJ2 is a PPARy ligand and efficiently promotes 
differentiation of C3Hl OT112 fibroblasts to adipocytes 
raises the interesting possibility that this PG serves as 
an adipogenic signaling molecule in vivo. Several PGs, 
including PGEz and prostacyclin, are known to be synthe- 
sized by isolated adipocytes as well as adipogenic cell 
lines and to exert marked effects on adipocyte differentia- 
tion (Christ and Nugteren, 1970; Axelrod and Levine, 
1981). Furthermore, phospholipase AP levels increase dur- 
ing the course of adipocyte differentiation, suggesting the 
potential for increased production of cyclooxygenase 
products (Gao and Serrero, 1990). Finally, abnormal PG 
synthesis has been reported in adipocytes isolated from 
obese Zucker rats (Gaskins et al., 1989). These results 
point to an important role for PGs in adipose tissue devel- 
opment and function. 
Synthesis of PGD2 has been reported to be low in ho- 
mogenates prepared from rat epididymal fat relative to 
other tissues (Ujihara et al., 1988). It remains possible 
that PGD2 and its PGJ2 metabolites are present at higher 
concentrations either locally or transiently during the 
course of adipocyte differentiation in the epididymal depot. 
However, PGD, has been shown to be the major PG syn- 
thesized in rat bone marrow homogenates (Kojima et al., 
1980; Ujihara et al., 1988). Bone marrow represents a 
highly active site for the recruitment of stromal cells to the 
adipocyte lineage as well as a site of abundant PPARy 
expression (Greene et al., 1995). Thus, PGD, metabolites 
such as 15-deoxy-A ‘*, 14-PGJ2 may serve as adipogenic 
signaling agents in the context of bone marrow. 
Evidence for a Novel PG Signaling Pathway 
The previous observations that PPARs are activated by 
high concentrations of fatty acids, regulate a battery of 
genes involved in lipid homeostasis, and play a crucial role 
in adipocyte differentiation suggested that the physiologic 
ligands for these receptors might be fatty acid metabolites. 
Our demonstration that the arachidonic acid derivative 15- 
deoxy-Ai*, “‘-PGJ2 binds PPARy supports this hypothesis. 
Nonetheless, the finding that a PG can serve as a ligand 
for a nuclear receptor is surprising in that most PGs are 
known to exert their effects on gene expression through 
interactions with cell surface receptors, inducing changes 
in the levels of second messengers. Our data indicate that 
the PGJ, series of PGs may bypass this second messen- 
ger signaling cascade and instead modulate the transcrip- 
tion of target genes directly through interactions with the 
PPAR family of ligand-activated transcription factors. Our 
results suggest the existence of a novel PG signaling path- 
way and, furthermore, raise the intriguing possibility that 
other eicosanoids may serve as ligands for additional or- 
phan members of the nuclear receptor superfamily. 
Experimental Procedures 
Chemicals 
All PGs were purchased from Cayman Chemical Company (Ann 
Arbor, Ml). 
Cotransfection Assay 
The pSG&GAL4-PPARa, pSG5GAL4-NUCl , and pSG5-GAL4PPARy 
chimeric receptor expression plasmids and (UAS)5-tk-CAT reporter 
plasmid were previously described (Lehmann et al., 1995). Transient 
cotransfection assays using the GAL4-PPAR chimeras were per- 
formed as previously described (Lehmann et al., 1995). 
Ligand Binding Assays 
To generate histidine-tagged PPARy ligand-binding domain protein, 
cDNA encoding the entire human PPARy ligand-binding domain 
(amino acids 176-477) (Greene et al., 1995) was amplified by PCR 
and inserted into the Ndel-BamHI sitesof bacterial expression plasmid 
PET-16b (Novagen). The His-PPARy ligand-binding domain protein 
was expressed in BL21(DE3)plysS cells and bacterial extracts pre- 
pared by freeze-thawing of the cells in lysis buffer containing 10 mM 
Tris (pH 8.0) 50 mM KCI, 10 mM DTT, and 1% Triton X-100 followed 
by centrifugation at 40,000 x g for 30 min. For competition binding 
assays, bacterial extracts (approximately 100 pg of protein) were incu- 
bated at 4OC for 2-3 hr with 10 nM PHlBRL49653 (specific activity, 
40 CVmmol) in the absence or presence of unlabeled competitor in 
buffer containing 10 mM Tris (pH 8.0), 50 mM KCI, 10 mM DTT. Bound 
wasseparatedfromfreeradioactivitybyelution through 1 ml Sephadex 
G-25 desalting columns (Boehringer Mannheim). Bound radioactivity 
eluted inthecolumnvoidvolumeandwasquantitated byliquidscintilla- 
tion counting. 
Adipocyte Differentiation Assays 
C3Hl OT112 clone 8 murine fibroblasts (American Type Culture Collec- 
tion) were maintained in Dulbecco’s modified Eagle’s medium (GIBCO, 
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Grand Island, NY) supplemented with 10% fetal calf serum and IO 
uglml penicillin and streptomycin. One day after reaching confluence, 
the cells were treated with BRL49653, ciglitazone, or PGs in the pres- 
ence of 200 nM insulin. Fresh media and test compounds were added 
two days postconfluence. Lipogenesis was measured in ceils at four 
days postconfluence as previously described (Moody et al., 1974). 
Accumulation of lipid droplets in the cytoplasm was determined by oil 
red 0 staining (Novikoff et al., 1980). 
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